{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
alpha-tocopherol acetate
to a specific field?
Status:
Investigational
Source:
NCT01621243: Phase 1/Phase 2 Interventional Terminated Metastatic Pancreatic Cancer
(2012)
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
NCT00268593: Phase 2 Interventional Completed Prostate Cancer
(2005)
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
NCT01943162: Not Applicable Interventional Completed PTSD With a History of Mild to Moderate TBI
(2012)
Source URL:
Class:
POLYMER
Conditions:
Mureletecan is a water-soluble prodrug, consisting of camptothecin covalently linked to polymeric backbone methacryloylglycynamide, with potential antineoplastic activity. After entering tumor cells, the active moiety camptothecin is slowly released from mureletecan via hydrolysis of the ester linkage. Camptothecin, the active moiety, is an alkaloid isolatable from the Chinese tree Camptotheca acuminata. Camptothecin itself suffers from poor solubility, which is why it is often investigated with a solubilizing conjugate; such as in Mureletecan. Camptothecin binds to and stabilizes the topoisomerase I-DNA covalent complex producing potentially lethal double-stranded DNA breaks when encountered by DNA replication machinery. Camptothecin has also been shown to inhibit HIF1a. Camptothecin has been investigated with a number of solubilizing conjugates as a potential treatment in various forms of cancer.
Status:
Investigational
Source:
NCT02515838: Phase 2 Interventional Completed Sickle-Cell Disease
(2015)
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
NCT01072747: Phase 3 Interventional Unknown status Prevention of Venous Thromboembolism
(2010)
Source URL:
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
US Previously Marketed
Source:
INNOHEP by LEO PHARMA AS
(2000)
Source URL:
First approved in 2000
Source:
INNOHEP by LEO PHARMA AS
Source URL:
Class:
POLYMER
Status:
US Previously Marketed
Source:
NORMIFLO by PHARMACIA AND UPJOHN
(1997)
Source URL:
First approved in 1997
Source:
NORMIFLO by PHARMACIA AND UPJOHN
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M015
(2025)
Source URL:
First approved in 2025
Source:
M015
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
POLYMER
